Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Standards May-June 09

This article was originally published in RAJ Devices

Executive Summary

International

You may also be interested in...



The US FDA’s Medical Device Postmarket Transformation Initiative

US manufacturers of medical devices can expect to see increased scrutiny of their postmarketing reports as the US Food and Drug Administration’s Center for Devices and Radiological Health takes action to strengthen its Medical Device Postmarket Transformation Initiative. The initiative, launched in 20061, was designed to increase the ability of CDRH to identify, analyse and act on postmarket information, thereby improving the safety and effectiveness of medical devices and radiation-emitting products. It is focused on execution in four areas: creating a culture of collaboration within CDRH, developing world-class data systems, enhancing risk:benefit communication efforts and collaborating on enforcement strategies and outcomes.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel